These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 30243479)

  • 1. [How to predict the relapse after surgery or radiofrequency of liver metastases of colorectal cancer? Interest of the serum kinetic variation of a matrix metalloproteinase cluster].
    Frenoux C; Rebischung C; Quesada JL; Mendosa C; Letoublon C; Trocmé C
    Bull Cancer; 2018 Oct; 105(10):884-895. PubMed ID: 30243479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Behavior of MMP-2, MMP-7, MMP-9, and Their Inhibitors TIMP-1 and TIMP-2 in Adenoma-Colorectal Cancer Sequence.
    Barabás L; Hritz I; István G; Tulassay Z; Herszényi L
    Dig Dis; 2021; 39(3):217-224. PubMed ID: 32961536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer.
    Oberg A; Höyhtyä M; Tavelin B; Stenling R; Lindmark G
    Anticancer Res; 2000; 20(2B):1085-91. PubMed ID: 10810401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The matrix metalloproteinase-7 and pro-enzyme of metalloproteinase-1 as a potential marker for patients with rectal cancer without distant metastasis.
    Fuksiewicz M; Kotowicz B; Rutkowski A; Kowalska M
    Tumour Biol; 2015 May; 36(5):3629-35. PubMed ID: 25549795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Matrix metalloproteinases and their tissue inhibitors in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis.
    Niebroj-Dobosz I; Janik P; Sokołowska B; Kwiecinski H
    Eur J Neurol; 2010 Feb; 17(2):226-31. PubMed ID: 19796283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in sera and tissue of patients with Dupuytren's disease.
    Ulrich D; Hrynyschyn K; Pallua N
    Plast Reconstr Surg; 2003 Oct; 112(5):1279-86. PubMed ID: 14504511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum MMP-8 and TIMP-1 predict prognosis in colorectal cancer.
    Böckelman C; Beilmann-Lehtonen I; Kaprio T; Koskensalo S; Tervahartiala T; Mustonen H; Stenman UH; Sorsa T; Haglund C
    BMC Cancer; 2018 Jun; 18(1):679. PubMed ID: 29929486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical relevance of the expression of mRNA of MMP-7, MMP-9, TIMP-1, TIMP-2 and CEA tissue samples from colorectal liver metastases.
    Sutnar A; Pesta M; Liska V; Treska V; Skalicky T; Kormunda S; Topolcan O; Cerny R; Holubec L
    Tumour Biol; 2007; 28(5):247-52. PubMed ID: 17992052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High Expression of MMP-9 in Primary Tumors and High Preoperative MPO in Serum Predict Improved Prognosis in Colorectal Cancer with Operable Liver Metastases.
    Peltonen R; Hagström J; Tervahartiala T; Sorsa T; Haglund C; Isoniemi H
    Oncology; 2021; 99(3):144-160. PubMed ID: 33027796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
    Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
    Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of repeated infliximab therapy on serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with rheumatoid arthritis.
    Klimiuk PA; Sierakowski S; Domyslawska I; Chwiecko J
    J Rheumatol; 2004 Feb; 31(2):238-42. PubMed ID: 14760791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum levels of TIMP-1 and MMP-7 as potential biomarkers in patients with metastatic colorectal cancer.
    Vočka M; Langer D; Fryba V; Petrtyl J; Hanus T; Kalousova M; Zima T; Petruzelka L
    Int J Biol Markers; 2019 Sep; 34(3):292-301. PubMed ID: 31578137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating gelatinases and tissue inhibitor of metalloproteinase-1 in colorectal cancer metastatic liver disease.
    Waas ET; Wobbes T; Ruers T; Lomme RM; Hendriks T
    Eur J Surg Oncol; 2006 Sep; 32(7):756-63. PubMed ID: 16650961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative estimation of matrix metalloproteinases 2 and 7 (MMP-2, MMP-7) and tissue inhibitors of matrix metalloproteinases 1 and 2 (TIMP-1, TIMP-2) in colorectal carcinoma tissue samples.
    Pesta M; Holubec L; Topolcan O; Cerna M; Rupert K; Holubec LS; Treska V; Kormunda S; Elgrova L; Finek J; Cerny R
    Anticancer Res; 2005; 25(5):3387-91. PubMed ID: 16101153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simultaneous up-regulation of matrix metalloproteinases 1, 2, 3, 7, 8, 9 and tissue inhibitors of metalloproteinases 1, 4 in serum of patients with chronic obstructive pulmonary disease.
    Navratilova Z; Zatloukal J; Kriegova E; Kolek V; Petrek M
    Respirology; 2012 Aug; 17(6):1006-12. PubMed ID: 22591289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Significance of Matrix Metalloproteinases in Blood Plasma of Patients with Gastric Cancer.
    Kushlinskii NE; Gershtein ES; Ivannikov AA; Davydov MM; Chang VL; Ognerubov NA; Stilidi IS
    Bull Exp Biol Med; 2019 Jan; 166(3):373-376. PubMed ID: 30627896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Significance of circulating matrix metalloproteinase-9 to tissue inhibitor of metalloproteinases-2 ratio as a predictor of disease progression in patients with metastatic renal cell carcinoma receiving sunitinib.
    Miyake H; Nishikawa M; Tei H; Furukawa J; Harada K; Fujisawa M
    Urol Oncol; 2014 Jul; 32(5):584-8. PubMed ID: 24680659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma MMP-2 and MMP-9 and their inhibitors TIMP-1 and TIMP-2 during human orthotopic liver transplantation. The effect of aprotinin and the relation to ischemia/reperfusion injury.
    Kuyvenhoven JP; Molenaar IQ; Verspaget HW; Veldman MG; Palareti G; Legnani C; Moolenburgh SE; Terpstra OT; Lamers CB; van Hoek B; Porte RJ
    Thromb Haemost; 2004 Mar; 91(3):506-13. PubMed ID: 14983226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preoperative levels of matrix metalloproteinase-7 and -9 and tissue inhibitor of matrix metalloproteinase-1 relation to pathologic parameters in bladder carcinoma patients.
    Gunes M; Kemik AS; Pirincci N; Gecit I; Taken K; Yuksel MB; Kaba M; Eryilmaz R
    Asian Pac J Cancer Prev; 2013; 14(2):873-6. PubMed ID: 23621254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparative study of protein expression in primary colorectal cancer and synchronous hepatic metastases: the significance of matrix metalloproteinase-1 expression as a predictor of liver metastasis.
    Kim YW; Ko YT; Kim NK; Chung HC; Min BS; Lee KY; Park JP; Kim H
    Scand J Gastroenterol; 2010; 45(2):217-25. PubMed ID: 20095886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.